The RNA Based Therapeutics and Vaccines Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or expand their existing operations in a new region.
CRISPR-based RNA Editing to Offer Lucrative Growth Prospects
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat) is an RNA-guided gene editing technique that inserts a double-strand break at a specific site in the genome using the Cas9 protein, which is obtained from bacteria. By using this technique, bacteria are able to seize brief nucleic acid sequences from invasive pathogens and mix them with the repeats in CRISPR loci. A group of bacterial endonucleases is directed by small RNAs generated by transcription of CRISPR loci to divide the genomes of invasive pathogens. This approach has gained acceptance as a potent method that makes genome editing possible in everyday life
Several new & existing DNA-editing companies have declared their ambition to expand into the RNA segment, and these include Boston, Massachusetts-based Beam Therapeutics, which has been researching CRISPR DNA editing as a treatment for several blood disorders. San Diego-based firm named Locana is also studying CRISPR-based RNA editing as a potential treatment for diseases like Huntington’s disease and motor-neuron disorder.
Numerous Development Potential of RNA-based Medicines
Since RNA-based therapies have the potential to cure both common and rare genetic illnesses, RNA-based therapies have attracted a lot of research. These types of studies are still in the pipeline, therefore businesses that commercialise these treatments first would have a competitive advantage over rivals. There are now just three commercially available RNA-based medicines based on antisense technology. Three ASO medicines have so far been approved by the FDA: nusinersen (Ionis Pharmaceuticals), eteplirsen (Sarepta Therapeutics), and inotersen (Ionis Pharmaceuticals and Akcea Therapeutics). As a result, there are numerous potential for the development and marketing of RNA-based medicines in the near future.
What Questions Should You Ask before Buying a Market Research Report?
• How is the RNA therapeutics market evolving?
• What is driving and restraining the RNA therapeutics market?
• How will each RNA therapeutics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each RNA therapeutics submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading RNA therapeutics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the RNA therapeutics projects for these leading companies?
• How will the industry evolve during the period between 2022 and 2032? What are the implications of
RNA therapeutics projects taking place now and over the next 10 years?
• Is there a greater need for product commercialization to further scale the RNA therapeutics market?
• Where is the RNA therapeutics market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the RNA therapeutics market today, and over the next 10 years:
• Our 223-page report provides 96 tables and 146 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the RNA therapeutics market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Type
• RNA Antisense Technologies
• RNA Interference (RNAi) Technologies
Application
• Genetic Disorders
– Spinal Muscular Atrophy (SMA)
– Cancer
– Acute Hepatic Porphyria (AHP)
– Duchenne Muscular Dystrophy (DMD)
– Others
• Autoimmune Disorders
– Ophthalmology
– Oncology
– Diabetes
– Rheumatoid Arthritis (RA)
– Others
End-user
• Research Institutes
• Hospitals & Clinics
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:
North America
• U.S.
• Canada
Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe
Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
MEA
• GCC
• South Africa
• Rest of MEA
Need industry data? Please contact us today.
The report also includes profiles and for some of the leading companies in the RNA Therapeutics Market, 2022 to 2032, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• Alnylam Pharmaceuticals, Inc.
• Arbutus Biopharma
• Arrowhead Pharmaceuticals, Inc.
• Benitec Biopharma
• Biogen
• Genzyme (Sanofi)
• Gradalis, Inc.
• Ionis Pharmaceuticals, Inc.
• Orna Therapeutics
• Sarepta Therapeutics, Inc.
• Silence Therapeutics
Overall world revenue for the RNA Therapeutics Market, 2022 to 2032 in terms of value the market will surpass US$6,992.1 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the RNA Therapeutics Market, 2022 to 2032 report help you?
In summary, our 210+ page report provides you with the following knowledge:
• Revenue forecasts to 2032 for RNA Therapeutics Market, 2022 to 2032 Market, with forecasts for type, application, and end-user each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2032 for five regional and 20 key national markets – See forecasts for the RNA Therapeutics Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 11 of the major companies involved in the RNA Therapeutics Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the RNA Therapeutics Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today RNA Based Therapeutics and Vaccines Market Report 2022-2032: Forecasts by Type (RNA Antisense Technologies, RNA Interference (RNAi) Technologies), by Application (Genetic Disorders (Spinal Muscular Atrophy, Cancer, Acute Hepatic Porphyria, Duchenne Muscular Dystrophy, Others), Autoimmune Disorders (Ophthalmology, Diabetes, Rheumatoid Arthritis, Others)), End-user (Research Institutes, Hospitals & Clinics) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to RNA Therapeutics Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered By This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.2 Market Restraining Factors
3.2.3 Market Opportunities
3.3 Market Trends
3.3.1 Safer Alternative to DNA Therapy
3.3.2 New Therapeutic Avenues Gaining Momentum
3.3.3 Versatility of RNA Molecules
3.3.4 RNA Therapeutics Pipeline Analysis
3.4 COVID-19 Impact Analysis
3.5 Porter’s Five Forces Analysis
3.5.1 Supplier Power
3.5.2 Buyer Power
3.5.3 Competitive Rivalry
3.5.4 Threat from Substitutes
3.5.5 Threat of New Entrants
3.6 RNA Therapies Sales Forecast by Drugs, 2022-2025
4 RNA Therapeutics Market Analysis by Technology
4.1 Key Findings
4.2 Type Segment Growth Prospects
4.3 RNA Therapeutics Market Size Estimation and Forecast by Type
4.4 RNA Antisense Technologies
4.4.1 Market Forecast by Region, 2022-2032 (US$ Mn)
4.4.2 Market Share by Region, 2022 & 2032 (%)
4.5 RNA Interference (RNAi) Technologies
4.5.1 Market Forecast by Region, 2022-2032 (US$ Mn)
4.5.2 Market Share by Region, 2022 & 2032 (%)
5 RNA Therapeutics Market Analysis by Application
5.1 Key Findings
5.2 Application Segment Growth Prospects
5.3 RNA Therapeutics Market Size Estimation and Forecast by Application
5.4 Genetic Disorders
5.4.1 Market Forecast by Region, 2022-2032 (US$ Mn)
5.4.2 Market Share by Region, 2022 & 2032 (%)
5.4.3 Market Forecast by Genetic Disorders, 2022-2032 (US$ Mn)
5.5 Autoimmune Disorders
5.5.1 Market Forecast by Region, 2022-2032 (US$ Mn)
5.5.2 Market Share by Region, 2022 & 2032 (%)
5.5.3 Market Forecast by Autoimmune Disorders, 2022-2032 (US$ Mn)
6 RNA Therapeutics Market Analysis by End-user
6.1 Key Findings
6.2 End-user Segment Growth Prospects
6.3 RNA Therapeutics Market Size Estimation and Forecast by End-user
6.4 Research Institutes
6.4.1 Market Forecast by Region, 2022-2032 (US$ Mn)
6.4.2 Market Share by Region, 2022 & 2032 (%)
6.5 Hospitals & Clinics
6.5.1 Market Forecast by Region, 2022-2032 (US$ Mn)
6.5.2 Market Share by Region, 2022 & 2032 (%)
7 RNA Therapeutics Market Analysis by Region
7.1 Key Findings
7.2 Regional Market Size Estimation and Forecast
7.3 COVID-19 Impact Analysis: Recovery Scenarios (V, U, W, L)
8 North America RNA Therapeutics Market Analysis
8.1 Key Findings
8.2 North America RNA Therapeutics Market Attractiveness Index
8.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
8.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
8.5 Market Size Estimation and Forecast by Type, 2022-2032 (US$ Mn)
8.6 Market Size Estimation and Forecast by Application, 2022-2032 (US$ Mn)
8.7 Market Size Estimation and Forecast by End-user, 2022-2032 (US$ Mn)
8.8 U.S.
8.9 Canada
9 Europe RNA Therapeutics Market Analysis
9.1 Key Findings
9.2 Europe RNA Therapeutics Market Attractiveness Index
9.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
9.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
9.5 Market Size Estimation and Forecast by Type, 2022-2032 (US$ Mn)
9.6 Market Size Estimation and Forecast by Application, 2022-2032 (US$ Mn)
9.7 Market Size Estimation and Forecast by End-user, 2022-2032 (US$ Mn)
9.8 Germany
9.9 UK
9.10 France
9.11 Italy
9.12 Spain
9.13 Rest of Europe
10 Asia Pacific RNA Therapeutics Market Analysis
10.1 Key Findings
10.2 Asia Pacific RNA Therapeutics Market Attractiveness Index
10.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
10.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
10.5 Market Size Estimation and Forecast by Type, 2022-2032 (US$ Mn)
10.6 Market Size Estimation and Forecast by Application, 2022-2032 (US$ Mn)
10.7 Market Size Estimation and Forecast by End-user, 2022-2032 (US$ Mn)
10.8 Japan
10.9 China
10.10 India
10.11 Australia
10.12 South Korea
10.13 Rest of Asia Pacific
11 Latin America RNA Therapeutics Market Analysis
11.1 Key Findings
11.2 Latin America RNA Therapeutics Market Attractiveness Index
11.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
11.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
11.5 Market Size Estimation and Forecast by Type, 2022-2032 (US$ Mn)
11.6 Market Size Estimation and Forecast by Application, 2022-2032 (US$ Mn)
11.7 Market Size Estimation and Forecast by End-user, 2022-2032 (US$ Mn)
11.8 Brazil
11.9 Mexico
11.10 Rest of Latin America
12 MEA RNA Therapeutics Market Analysis
12.1 Key Findings
12.2 MEA RNA Therapeutics Market Attractiveness Index
12.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
12.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn)
12.5 Market Size Estimation and Forecast by Type, 2022-2032 (US$ Mn)
12.6 Market Size Estimation and Forecast by Application, 2022-2032 (US$ Mn)
12.7 Market Size Estimation and Forecast by End-user, 2022-2032 (US$ Mn)
12.8 GCC
12.9 South Africa
12.10 Rest of MEA
13 Company Profiles
13.1 Key Business Strategies
13.2 Alnylam Pharmaceuticals, Inc.
13.2.1 Company Snapshot
13.2.2 Company Overview
13.2.3 Financial Analysis
13.2.4 Product Benchmarking
13.2.5 Strategic Outlook
13.3 Arbutus Biopharma
13.3.1 Company Snapshot
13.3.2 Company Overview
13.3.3 Financial Analysis
13.3.4 Product Benchmarking
13.3.5 Strategic Outlook
13.4 Arrowhead Pharmaceuticals, Inc.
13.4.1 Company Snapshot
13.4.2 Company Overview
13.4.3 Financial Analysis
13.4.4 Product Benchmarking
13.4.5 Strategic Outlook
13.5 Benitec Biopharma
13.5.1 Company Snapshot
13.5.2 Company Overview
13.5.3 Financial Analysis
13.5.4 Product Benchmarking
13.6 Biogen
13.6.1 Company Snapshot
13.6.2 Company Overview
13.6.3 Financial Analysis
13.6.4 Product Benchmarking
13.6.5 Strategic Outlook
13.7 Genzyme (Sanofi)
13.7.1 Company Snapshot
13.7.2 Company Overview
13.7.3 Financial Analysis
13.7.4 Product Benchmarking
13.7.5 Strategic Outlook
13.8 Gradalis, Inc.
13.8.1 Company Snapshot
13.8.2 Company Overview
13.8.3 Product Benchmarking
13.9 Ionis Pharmaceuticals, Inc.
13.9.1 Company Snapshot
13.9.2 Company Overview
13.9.3 Financial Analysis
13.9.4 Product Benchmarking
13.9.5 Strategic Outlook
13.10 Orna Therapeutics
13.10.1 Company Snapshot
13.10.2 Company Overview
13.10.3 Product Benchmarking
13.10.4 Strategic Outlook
13.11 Sarepta Therapeutics, Inc.
13.11.1 Company Snapshot
13.11.2 Company Overview
13.11.3 Financial Analysis
13.11.4 Product Benchmarking
13.11.5 Strategic Outlook
13.12 Silence Therapeutics
13.12.1 Company Snapshot
13.12.2 Company Overview
13.12.3 Financial Analysis
13.12.4 Product Benchmarking
14 Conclusion and Recommendations
14.1 Concluding Remarks from Visiongain
14.2 Recommendations for Market Players
List of Tables
Table 1 RNA Therapeutics Market Snapshot, 2022 & 2032 (US$ million, CAGR %)
Table 2 Status of RNA Therapies
Table 3 RNA Therapeutics Pipeline Analysis
Table 4 RNA Therapeutics Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 5 RNA Therapeutics Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 6 RNA Therapeutics Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 7 RNA Therapeutics Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 8 RNA Therapies Sales Forecast, 2022-2025 (US$ mn, AGR%)
Table 9 Spinraza Market Shares by Region, 2019-2021
Table 10 RNA Therapeutics Market Forecast by Technology, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 11 RNA Antisense Technologies Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 12 RNA Interference (RNAi) Technologies Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 13 RNA Therapeutics Market Forecast by Application, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 14 Genetic Disorders Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 15 RNA Therapeutics Market Forecast by Genetic Disorders, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 16 Autoimmune Disorders Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 17 RNA Therapeutics Market Forecast by Autoimmune Disorders, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 18 RNA Therapeutics Market Forecast by End-user, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 19 Research Institutes Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 20 Hospitals & Clinics Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 21 RNA Therapeutics Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 22 RNA Therapeutics Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 23 RNA Therapeutics Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 24 RNA Therapeutics Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 25 RNA Therapeutics Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 26 North America RNA Therapeutics Market Forecast by Country, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 27 North America RNA Therapeutics Market Forecast by Type, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 28 North America RNA Therapeutics Market Forecast by Application, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 29 North America RNA Therapeutics Market Forecast by End-user, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 30 U.S. RNA Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 31 Canada RNA Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 32 Europe RNA Therapeutics Market Forecast by Country, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 33 Europe RNA Therapeutics Market Forecast by Type, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 34 Europe RNA Therapeutics Market Forecast by Application, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 35 Europe RNA Therapeutics Market Forecast by End-user, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 36 Germany RNA Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 37 UK RNA Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 38 France RNA Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 39 Italy RNA Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 40 Spain RNA Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 41 Rest of Europe RNA Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 42 Asia Pacific RNA Therapeutics Market Forecast by Country, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 43 Asia Pacific RNA Therapeutics Market Forecast by Type, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 44 Asia Pacific RNA Therapeutics Market Forecast by Application, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 45 Asia Pacific RNA Therapeutics Market Forecast by End-user, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 46 Japan RNA Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 47 China RNA Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 48 India RNA Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 49 Australia RNA Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 50 South Korea RNA Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 51 Rest of Asia Pacific RNA Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 52 Latin America RNA Therapeutics Market Forecast by Country, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 53 Latin America RNA Therapeutics Market Forecast by Type, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 54 Latin America RNA Therapeutics Market Forecast by Application, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 55 Latin America RNA Therapeutics Market Forecast by End-user, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 56 Brazil RNA Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 57 Mexico RNA Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 58 Rest of Latin America RNA Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 59 MEA RNA Therapeutics Market Forecast by Country, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 60 MEA RNA Therapeutics Market Forecast by Type, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 61 MEA RNA Therapeutics Market Forecast by Application, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 62 MEA RNA Therapeutics Market Forecast by End-user, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 63 GCC RNA Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 64 South Africa RNA Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 65 Rest of MEA RNA Therapeutics Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%)
Table 66 Key Business Strategies
Table 67 Alnylam Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 68 Alnylam Pharmaceuticals, Inc.: Product Benchmarking
Table 69 Alnylam Pharmaceuticals, Inc.: Strategic Outlook
Table 70 Arbutus Biopharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 71 Arbutus Biopharma: Product Benchmarking
Table 72 Arbutus Biopharma: Strategic Outlook
Table 73 Arrowhead Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 74 Arrowhead Pharmaceuticals, Inc.: Product Benchmarking
Table 75 Arrowhead Pharmaceuticals, Inc.: Strategic Outlook
Table 76 Benitec Biopharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 77 Benitec Biopharma: Product Benchmarking
Table 78 Biogen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 79 Biogen: Product Benchmarking
Table 80 Biogen: Strategic Outlook
Table 81 Genzyme (Sanofi): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 Genzyme (Sanofi): Product Benchmarking
Table 83 Genzyme (Sanofi): Strategic Outlook
Table 84 Gradalis, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 Gradalis, Inc.: Product Benchmarking
Table 86 Ionis Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 Ionis Pharmaceuticals, Inc.: Product Benchmarking
Table 88 Ionis Pharmaceuticals, Inc.: Strategic Outlook
Table 89 Orna Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Orna Therapeutics: Product Benchmarking
Table 91 Orna Therapeutics: Strategic Outlook
Table 92 Sarepta Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 Sarepta Therapeutics, Inc.: Product Benchmarking
Table 94 Sarepta Therapeutics, Inc.: Strategic Outlook
Table 95 Silence Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 Silence Therapeutics: Product Benchmarking
List of Figures
Figure 1 RNA Therapeutics Market Segmentation
Figure 2 RNA Therapeutics Market by Type: Market Attractiveness Index
Figure 3 RNA Therapeutics Market by Application: Market Attractiveness Index
Figure 4 RNA Therapeutics Market by End-user: Market Attractiveness Index
Figure 5 RNA Therapeutics Market Attractiveness Index by Region
Figure 6 RNA Therapeutics Market: Market Dynamics
Figure 7 Alliance, Acquisition, and Financing in Gene, Cell, & RNA Therapy
Figure 8 RNA Therapy Pipeline: Most Common Modalities
Figure 9 RNA Therapy Clinical Trials Pipeline
Figure 10 COVID Impact Analysis: RNA Therapeutics Market Recovery Scenarios
Figure 11 RNA Therapeutics Market by Region, 2022-2032 (US$ Mn, AGR %): “V” Shaped Recovery
Figure 12 RNA Therapeutics Market by Region, 2022-2032 (US$ Mn, AGR %): “U” Shaped Recovery
Figure 13 RNA Therapeutics Market by Region, 2022-2032 (US$ Mn, AGR %): “W” Shaped Recovery
Figure 14 RNA Therapeutics Market by Region, 2022-2032 (US$ Mn, AGR %): “L” Shaped Recovery
Figure 15 RNA Therapeutics Market: Porter’s Five Forces Analysis
Figure 16 RNA Therapeutics Market Attractiveness Index by Technology
Figure 17 RNA Therapeutics Market Forecast by Type, 2022-2032 (US$ million)
Figure 18 RNA Therapeutics Market Share Forecast by Type, 2022, 2027, 2032 (%)
Figure 19 RNA Antisense Technologies Market Forecast by Region, 2022-2032 (US$ million)
Figure 20 RNA Antisense Technologies Market Share Forecast by Region, 2022 & 2032 (%)
Figure 21 RNA Interference (RNAi) Technologies Market Forecast by Region, 2022-2032 (US$ million)
Figure 22 RNA Interference (RNAi) Technologies Market Share Forecast by Region, 2022 & 2032 (%)
Figure 23 RNA Therapeutics Market Attractiveness Index by Type
Figure 24 RNA Therapeutics Market Forecast by Application, 2022-2032 (US$ million)
Figure 25 RNA Therapeutics Market Share Forecast by Application, 2022, 2027, 2032 (%)
Figure 26 Genetic Disorders Market Forecast by Region, 2022-2032 (US$ million)
Figure 27 Genetic Disorders Market Share Forecast by Region, 2022 & 2032 (%)
Figure 28 RNA Therapeutics Market Forecast by Genetic Disorders, 2022-2032 (US$ million)
Figure 29 Autoimmune Disorders Market Forecast by Region, 2022-2032 (US$ million)
Figure 30 Autoimmune Disorders Market Share Forecast by Region, 2022 & 2032 (%)
Figure 31 RNA Therapeutics Market Forecast by Autoimmune Disorders, 2022-2032 (US$ million)
Figure 32 RNA Therapeutics Market Attractiveness Index by End-user
Figure 33 RNA Therapeutics Market Forecast by End-user, 2022-2032 (US$ million)
Figure 34 RNA Therapeutics Market Share Forecast by End-user, 2022, 2027, 2032 (%)
Figure 35 Research Institutes Market Forecast by Region, 2022-2032 (US$ million)
Figure 36 Research Institutes Market Share Forecast by Region, 2022 & 2032 (%)
Figure 37 Hospitals & Clinics Market Forecast by Region, 2022-2032 (US$ million)
Figure 38 Hospitals & Clinics Market Share Forecast by Region, 2022 & 2032 (%)
Figure 39 RNA Therapeutics Market Forecast by Region 2022 & 2032 (Revenue, CAGR%)
Figure 40 RNA Therapeutics Market Share Forecast by Region 2022, 2027, 2032(%)
Figure 41 RNA Therapeutics Market by Region, 2022-2032 (US$ Mn)
Figure 42 RNA Therapeutics Market by Region, 2022-2032 (US$ Mn, AGR %): “V” Shaped Recovery
Figure 43 RNA Therapeutics Market by Region, 2022-2032 (US$ Mn, AGR %): “U” Shaped Recovery
Figure 44 RNA Therapeutics Market by Region, 2022-2032 (US$ Mn, AGR %): “W” Shaped Recovery
Figure 45 RNA Therapeutics Market by Region, 2022-2032 (US$ Mn, AGR %): “L” Shaped Recovery
Figure 46 North America RNA Therapeutics Market Attractiveness Index
Figure 47 North America RNA Therapeutics Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 48 North America RNA Therapeutics Market Forecast by Country, 2022-2032 (US$ million)
Figure 49 North America RNA Therapeutics Market Share Forecast by Country, 2022 & 2032 (%)
Figure 50 North America RNA Therapeutics Market Forecast by Type, 2022-2032 (US$ million)
Figure 51 North America RNA Therapeutics Market Share Forecast by Type, 2022 & 2032 (%)
Figure 52 North America RNA Therapeutics Market Forecast by Application, 2022-2032 (US$ million)
Figure 53 North America RNA Therapeutics Market Share Forecast by Application, 2022 & 2032 (%)
Figure 54 North America RNA Therapeutics Market Forecast by End-user, 2022-2032 (US$ million)
Figure 55 North America RNA Therapeutics Market Share Forecast by End-user, 2022 & 2032 (%)
Figure 56 U.S. RNA Therapeutics Market Forecast, 2022-2032 (US$ million)
Figure 57 Canada RNA Therapeutics Market Forecast, 2022-2032 (US$ million)
Figure 58 Europe RNA Therapeutics Market Attractiveness Index
Figure 59 Europe RNA Therapeutics Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 60 Europe RNA Therapeutics Market Forecast by Country, 2022-2032 (US$ million)
Figure 61 Europe RNA Therapeutics Market Share Forecast by Country, 2022 & 2032 (%)
Figure 62 Europe RNA Therapeutics Market Forecast by Type, 2022-2032 (US$ million)
Figure 63 Europe RNA Therapeutics Market Share Forecast by Type, 2022 & 2032 (%)
Figure 64 Europe RNA Therapeutics Market Forecast by Application, 2022-2032 (US$ million)
Figure 65 Europe RNA Therapeutics Market Share Forecast by Application, 2022 & 2032 (%)
Figure 66 Europe RNA Therapeutics Market Forecast by End-user, 2022-2032 (US$ million)
Figure 67 Europe RNA Therapeutics Market Share Forecast by End-user, 2022 & 2032 (%)
Figure 68 Germany RNA Therapeutics Market Forecast, 2022-2032 (US$ million)
Figure 69 UK RNA Therapeutics Market Forecast, 2022-2032 (US$ million)
Figure 70 France RNA Therapeutics Market Forecast, 2022-2032 (US$ million)
Figure 71 Italy RNA Therapeutics Market Forecast, 2022-2032 (US$ million)
Figure 72 Spain RNA Therapeutics Market Forecast, 2022-2032 (US$ million)
Figure 73 Rest of Europe RNA Therapeutics Market Forecast, 2022-2032 (US$ million)
Figure 74 Asia Pacific RNA Therapeutics Market Attractiveness Index
Figure 75 Asia Pacific RNA Therapeutics Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 76 Asia Pacific RNA Therapeutics Market Forecast by Country, 2022-2032 (US$ million)
Figure 77 Asia Pacific RNA Therapeutics Market Share Forecast by Country, 2022 & 2032 (%)
Figure 78 Asia Pacific RNA Therapeutics Market Forecast by Type, 2022-2032 (US$ million)
Figure 79 Asia Pacific RNA Therapeutics Market Share Forecast by Type, 2022 & 2032 (%)
Figure 80 Asia Pacific RNA Therapeutics Market Forecast by Application, 2022-2032 (US$ million)
Figure 81 Asia Pacific RNA Therapeutics Market Share Forecast by Application, 2022 & 2032 (%)
Figure 82 Asia Pacific RNA Therapeutics Market Forecast by End-user, 2022-2032 (US$ million)
Figure 83 Asia Pacific RNA Therapeutics Market Share Forecast by End-user, 2022 & 2032 (%)
Figure 84 Japan RNA Therapeutics Market Forecast, 2022-2032 (US$ million)
Figure 85 China RNA Therapeutics Market Forecast, 2022-2032 (US$ million)
Figure 86 India RNA Therapeutics Market Forecast, 2022-2032 (US$ million)
Figure 87 Australia RNA Therapeutics Market Forecast, 2022-2032 (US$ million)
Figure 88 South Korea RNA Therapeutics Market Forecast, 2022-2032 (US$ million)
Figure 89 Rest of Asia Pacific RNA Therapeutics Market Forecast, 2022-2032 (US$ million)
Figure 90 Latin America RNA Therapeutics Market Attractiveness Index
Figure 91 Latin America RNA Therapeutics Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 92 Latin America RNA Therapeutics Market Forecast by Country, 2022-2032 (US$ million)
Figure 93 Latin America RNA Therapeutics Market Share Forecast by Country, 2022 & 2032 (%)
Figure 94 Latin America RNA Therapeutics Market Forecast by Type, 2022-2032 (US$ million)
Figure 95 Latin America RNA Therapeutics Market Share Forecast by Type, 2022 & 2032 (%)
Figure 96 Latin America RNA Therapeutics Market Forecast by Application, 2022-2032 (US$ million)
Figure 97 Latin America RNA Therapeutics Market Share Forecast by Application, 2022 & 2032 (%)
Figure 98 Latin America RNA Therapeutics Market Forecast by End-user, 2022-2032 (US$ million)
Figure 99 Latin America RNA Therapeutics Market Share Forecast by End-user, 2022 & 2032 (%)
Figure 100 Brazil RNA Therapeutics Market Forecast, 2022-2032 (US$ million)
Figure 101 Mexico RNA Therapeutics Market Forecast, 2022-2032 (US$ million)
Figure 102 Rest of Latin America RNA Therapeutics Market Forecast, 2022-2032 (US$ million)
Figure 103 MEA RNA Therapeutics Market Attractiveness Index
Figure 104 MEA RNA Therapeutics Market by Region, 2022, 2027 & 2032 (US$ million)
Figure 105 MEA RNA Therapeutics Market Forecast by Country, 2022-2032 (US$ million)
Figure 106 MEA RNA Therapeutics Market Share Forecast by Country, 2022 & 2032 (%)
Figure 107 MEA RNA Therapeutics Market Forecast by Type, 2022-2032 (US$ million)
Figure 108 MEA RNA Therapeutics Market Share Forecast by Type, 2022 & 2032 (%)
Figure 109 MEA RNA Therapeutics Market Forecast by Application, 2022-2032 (US$ million)
Figure 110 MEA RNA Therapeutics Market Share Forecast by Application, 2022 & 2032 (%)
Figure 111 MEA RNA Therapeutics Market Forecast by End-user, 2022-2032 (US$ million)
Figure 112 MEA RNA Therapeutics Market Share Forecast by End-user, 2022 & 2032 (%)
Figure 113 GCC RNA Therapeutics Market Forecast, 2022-2032 (US$ million)
Figure 114 South Africa RNA Therapeutics Market Forecast, 2022-2032 (US$ million)
Figure 115 Rest of MEA RNA Therapeutics Market Forecast, 2022-2032 (US$ million)
Figure 116 Alnylam Pharmaceuticals, Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 117 Alnylam Pharmaceuticals, Inc.: Product Revenue Shares (%), 2021
Figure 118 Alnylam Pharmaceuticals, Inc.: Business Operations Shares (%), 2021
Figure 119 Alnylam Pharmaceuticals, Inc.: Gross Profit, 2017-2021 (US$ million, AGR%)
Figure 120 Alnylam Pharmaceuticals, Inc.: R&D, 2017-2021 (US$ million, AGR%)
Figure 121 Arbutus Biopharma: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 122 Arbutus Biopharma: Gross Profit, 2017-2021 (US$ million, AGR%)
Figure 123 Arbutus Biopharma: R&D, 2017-2021 (US$ million, AGR%)
Figure 124 Arrowhead Pharmaceuticals, Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 125 Arrowhead Pharmaceuticals, Inc.: Gross Profit, 2017-2021 (US$ million, AGR%)
Figure 126 Arrowhead Pharmaceuticals, Inc.: R&D, 2017-2021 (US$ million, AGR%)
Figure 127 Benitec Biopharma: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 128 Benitec Biopharma: Gross Profit, 2017-2021 (US$ million, AGR%)
Figure 129 Benitec Biopharma: R&D, 2017-2021 (US$ million, AGR%)
Figure 130 Biogen: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 131 Biogen: Regional Market Shares (%), 2021
Figure 132 Biogen: Gross Profit, 2017-2021 (US$ million, AGR%)
Figure 133 Biogen: R&D, 2017-2021 (US$ million, AGR%)
Figure 134 Genzyme (Sanofi): Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 135 Genzyme (Sanofi): Regional Market Shares (%), 2021
Figure 136 Genzyme (Sanofi): Gross Profit, 2017-2021 (US$ million, AGR%)
Figure 137 Genzyme (Sanofi): R&D, 2017-2021 (US$ million, AGR%)
Figure 138 Ionis Pharmaceuticals, Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 139 Ionis Pharmaceuticals, Inc.: Gross Profit, 2017-2021 (US$ million, AGR%)
Figure 140 Ionis Pharmaceuticals, Inc.: R&D, 2017-2021 (US$ million, AGR%)
Figure 141 Sarepta Therapeutics, Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 142 Sarepta Therapeutics, Inc.: Gross Profit, 2017-2021 (US$ million, AGR%)
Figure 143 Sarepta Therapeutics, Inc.: R&D, 2017-2021 (US$ million, AGR%)
Figure 144 Silence Therapeutics: Net Revenue, 2020-2021 (US$ million)
Figure 145 Silence Therapeutics: Gross Profit, 2020-2021 (US$ million)
Figure 146 Silence Therapeutics: R&D, 2020-2021 (US$ million)
List of Companies Profiled in the Report
Alnylam Pharmaceuticals, Inc.
Arbutus Biopharma
Arrowhead Pharmaceuticals, Inc.
Benitec Biopharma
Biogen
Genzyme (Sanofi)
Gradalis, Inc.
Ionis Pharmaceuticals, Inc.
Orna Therapeutics
Sarepta Therapeutics, Inc.
Silence Therapeutics
List of Other Companies Mentioned in the Report
AGC Biologics
Beam Therapeutics
Boehringer Ingelheim
CRISPR Therapeutics
Curia
Delphi Genetics
Eurofins Genomics
Fujifilm Diosynth Biotechnologies
Hanmi Pharmaceutical Group
Intellia Therapeutics
Lonza
Precision Nanosystems
Regeneron
Samsung Biologics
Sigma Aldrich
Thermo Fisher Scientific Inc.
VIVEbiotech
Wuxi Apptec
List of Associations Mentioned in the Report
Biomedical Advanced Research and Development Authority (BARDA)
Centers for Disease Control and Prevention (CDC)
Coalition for Epidemic Preparedness Innovations (CEPI)
Committee for Medicinal Products for Human Use (CHMP)
European Commission (EC)
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
GAVI
Haute Autorité de santé (HAS)
Indian Council of Medical Research (ICMR)
International AIDS Vaccine Initiative (IAVI)
King Abdulaziz University (KAU)
Medicines and Healthcare products Regulatory Agency (MHRA)
National Health Service (NHS)
National Institute of Virology (NIV)
Russian Direct Investment Fund (RDIF)
Servizio Sanitario Nazionale (SSN)
United Nations Children's Fund (UNICEF)
University of Saskatchewan (USask, Canada)
University of Zaragoza
US Department of Health and Human Services (HHS)
Vaccine and Infectious Disease Organization (VIDO)
World Health Organization (WHO)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
